Introduction
Numerous papers dealing with chemotherapy management of neoplastic diseases have reported mitoxantrone to be an important modern therapeutic both in studies involving mice [1, 2] and also humans [3] [4] [5] [6] . Reported adverse effects -nausea, vomiting, myelotoxicity, anemia, cardiotoxicity and immunosuppression -are usually mild or moderate in comparison to other drugs of the same group [6, 7] . For mitoxantrone, as with many other chemotherapeutic regimens, there is also a relationship between the dose of the drug and its pharmacological response. Higher doses kill greater numbers of tumor cells, though as drug doses are increased, toxicity to normal tissue also increases. Combination therapy with multiple drugs is a common practice in the treatment of cancer. L-carnitine, a vitamin-like substance known to have both hepatoprotective and cardioprotective effects, could be a good candidate to modulate the toxicity profile of anti-cancer drugs, especially those with an alkylating mechanism of action [8] [9] [10] [11] .
We have previously reported [12] that therapeutic effects of MX-LCAR combination therapy on an experimental solid form of Ehrlich tumor in mice can be expected at high doses of both drugs, based on values calculated from an index of relative hazard. In this study, we investigated the effect of LCAR on the lethal toxicity of intravenous administration of single-doses of MX into mice.
We used the dose -lethality relationship to evaluate the toxicity of MX in laboratory animals and subsequent probit analysis for quantification of the toxicity. We present our new findings and also discuss the use of toxicity data in assessing the safety of the MX-LCAR combination therapy.
Experimental Procedures

Materials
Mitoxantrone (MX), 1,4-dihydroxy-5,8-bis{[2-/ (2-hydroxyethyl)amino/ethyl]amino)} anthracene-9,10-dione dihydrochloride (see Figure 1) was purchased from the Research Institute of Pharmacy and Biochemistry in Prague. It is a dark blue hygroscopic crystalline substance, soluble in water, in physiological saline, and in isotonic glucose solution, with a molecular weight of 517.41.
L-carnitine (LCAR; L-beta-hydroxy-gamma-Ntrimethylaminobutyric acid) (see Figure 2 ) is an active form of the original commercial preparation L-CARNITIN, inj. 5×5 ml à 1 g (Leopold Pharma, Graz, Austria).
Determination of the median lethal dose (LD 50 )
NMRI female mice weighing 25-30 g were obtained from the Konárovice breeding farm. Animals were housed in clean conditions with access to a standard diet of Altromin 1320 (Velaz, A.S.) and water ad libitum. Mice were divided into twelve groups of ten animals each: six control groups of MX alone and six test groups of the combination (MX-LCAR). Both MX and LCAR were administered intravenously in volumes of 0.4 ml and/or 0.2 ml (low dose) per 20 g of body weight on the first day of the experiment. Animals in the first six groups (MX alone) were treated intravenously with single doses of MX at 7, 9, 11, 13, 15 or 17 mg kg -1 . Animals in the six test groups were administered the combination of MX intravenously at the same single doses of 7, 9, 11, 13, 15 or 17 mg kg -1 and LCAR intravenously at a single dose of 200 mg kg -1 . LCAR was administered at the same time as the MX. The 200 mg kg -1 dose of LCAR was estimated from our previous experiments. The experiment was ended after 45 days. The survival of mice and lethality of drugs in each group of the combination of MX-LCAR was compared to that of the corresponding control group (MX alone). The handling and treatment of mice were the same for all animals and conformed to European Union recommendations on the handling of experimental animals. The experimental protocol was approved by the ethical commission of Charles University in the Czech Republic.
Statistical analysis
The LD 50 was calculated for each dose of MX alone and in combination with LCAR. Probit analysis [13] was used to evaluate the experimental results. After logarithmic transformation of the doses, the probability of death was modeled by the Gauss distribution. Microsoft Excel was used for construction of graphs. The differences in the LD 50 values were estimated using the chi-square test at the 0.05 level of significance.
Results
The survival of mice after treatment with a single intravenous injection of MX given at different doses, either alone or combined with LCAR at a single dose of 200 mg kg -1 , was studied in NMRI mice. Toxicity was estimated as the occurrence of death within a 45-day observation period. The survival of mice in each MX group was compared to that of the corresponding MX-LCAR group. Table 2 . Effect of MX and MX-LCAR on the lethality of mice.
Effect of MX and MX-LCAR combination treatment on the survival and lethality of mice
differences in the geometric mean of survival time were observed only at a dose of MX of 15 mg kg -1 compared to the corresponding group of MX-LCAR. Mitoxantrone -L-carnitine combination treatment at this dose produced a mean of survival 39.4 days [CI 95% (29.2-53.2)], which is about 79% longer than did mice treated only with MX at the same dose (15 mg kg -1 ). The log-rank test yields a p-value of 0.02567, thus the relationship between the treatment and response survival at this dose is statistically significant.
NMRI female mice weighing 25-30 g, were divided into twelve groups: six control groups of MX and six test groups of the combination MX-LCAR. MX was administered intravenously at single doses of 7, 9, 11, 13, 15 or 17 mg kg -1 and LCAR intravenously at a single dose of 200 mg kg -1 . The table shows the doses of MX and MX-LCAR, the geometric mean of survival, the confidence interval, and the percent of surviving mice.
The lethality of MX increased in a dose-dependent manner. In the group treated with MX alone (see Table 2 ), 9 mg kg -1 was already the lowest dose that resulted in death, whereas in the group treated with MX and LCAR, death occurred first at a dose of 13 mg kg -1 ( Table 2 ).
The probability of death as a function of the dose and corresponding LD 50 values were determined for MX-LCAR and compared to MX alone (Table 2) . A graphical illustration of these relationships is shown in Figure 3 . The figure shows the dependence of the probability of death on doses of MX alone or when combined with a single dose of LCAR (200 mg kg -1 ). As can be seen in Figure 3 , there is a striking difference between the LD 50 values for the two treatments. A chi-square test of the hypothesis of equality of the two distributions was rejected at a 0.05 level of significance.
NMRI female mice weighing 25-30 g, were divided into twelve groups: six control groups of MX and six test groups of the combination MX-LCAR. MX was administered intravenously at single doses of 7, 9, 11, 13, 15 or 17 mg kg -1 and LCAR intravenously at a single dose of 200 mg kg -1 . The table shows the dose of MX in mg kg -1 , the number of deaths per dose of mitoxantrone and compares the lethality of the combination MX-LCAR to the MX alone controls.
Dose-lethality relationships in the study of the acute toxicity of MX compared to MX-LCAR combination treatment in healthy NMRI mice. The figure shows the dependence of the probability of death on doses of MX and MX-LCAR at a single dose of 200 mg kg -1 . LD 50 of MX alone was 15.2 mg kg -1 whereas in combination with LCAR administered intravenously at a single dose of 200 mg kg -1 the LD 50 was 21.8 mg kg -1 . The relative toxicity, given as a ratio of LD 50 of MX to the LD 50 of MX-LCAR, was 69.7%.
At all doses of MX used in our experiment, the number of animals that survived was greater only when MX was combined with LCAR. An enhanced toxicity to MX was observed if doses higher than 15 mg kg -1 were administered (60% mortality). Simultaneous application of LCAR decreased the lethal toxicity of MX (15 mg kg -1 ) to 10%. No difference was observed in the case of the highest dose of MX used (mortality 60% in the MX group and 50% in the MX+LCAR group).
LD 50 for MX alone was 15.2 mg kg -1 , whereas in combination with LCAR it increased to 21.8 mg kg -1 . Our results suggest that LCAR somewhat increases the LD 50 of MX when both drugs are administered to mice.
Discussion
Our results support the conclusion that the addition of LCAR increases the LD 50 of MX in mice. The most important and well-known side effect of anthraquinone cytostatics is their cardiotoxic effect. Therefore, we used LCAR not only for its cardioprotective effect but also for its possible beneficial role in cellular metabolism. Carnitine derivatives play an important role in lipid metabolism acting as carriers of long chain fatty acids through the inner mitochondrial membrane to deliver substrates for β-oxidation. In this way, carnitine could support the nutrition of normal cells and contribute to their protection against the detrimental effects of the cytostatic compound. In our previous study [12] , two doses of MX (3 or 6 mg kg -1 ) in combination with LCAR (200 mg kg -1 ) were administered to mice bearing the solid form of Ehrlich tumor. The results of the abovementioned study, based on an index of relative hazard, suggested using a higher dose of both drugs. In this study, we investigated the effect of LCAR on the lethal toxicity of MX on mice. Figure 3 shows the dependence of the probability of death related to the dose of MX either alone or combined with a single dose of LCAR (200 mg kg -1 )
.
The LD 50 of MX alone in our application was 15.2 mg kg -1 , whereas in combination with L-CAR at a dose of 200 mg kg -1 , the LD 50 was 21.8 mg kg -1 . The estimates of LD 50 give us a better idea as to the acute toxicity of MX when MX was administered alone and in combination with LCAR. Mice that received the combination of MX and LCAR had a lower risk of death compared to the corresponding group of animals that was administered MX alone. Moreover, our new findings strongly support the idea that LCAR influences the toxicity profile of MX, especially at doses close to the LD 50 . At this dose, LCAR increases the relative safety of the drug combination. Succinctly, LCAR administered with MX may protect against drug-induced toxicity. The values of the LD 50 we have obtained will be used to guide the design of future experiments.
